Journal Article

Q151M-Mediated Multinucleoside Resistance: Prevalence, Risk Factors, and Response to Salvage Therapy

Mauro Zaccarelli, Carlo Federico Perno, Federica Forbici, Fabio Soldani, Sandro Bonfigli, Caterina Gori, Maria Paola Trotta, Maria Concetta Bellocchi, Giuseppina Liuzzi, Roberta D'Arrigo, Patrizio De Longis, Evangelo Boumis, Rita Bellagamba, Valerio Tozzi, Pasquale Narciso and Andrea Antinori

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 38, issue 3, pages 433-437
Published in print February 2004 | ISSN: 1058-4838
Published online February 2004 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/381097
Q151M-Mediated Multinucleoside Resistance: Prevalence, Risk Factors, and Response to Salvage Therapy

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Among 470 patients with acquired immune deficiency syndrome and/or human immunodeficiency virus infection (HIV/AIDS) who underwent genotype resistance testing (GRT) after the failure of therapy, 17 (3.6%) harbored the Q151M mutation. The Q151M mutation was associated with younger age, lower CD4+ lymphocyte count, higher HIV RNA level, and treatment with >2 pre-GRT regimens. By contrast, the Q151M mutation was inversely associated with lamivudine administration. A full reversion of the Q151M mutation was observed in 5 of 5 patients who underwent treatment interruption after GRT. The reversion was followed by a response to salvage therapy in 4 (80%) of 5 patients.

Journal Article.  2670 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.